Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ryoko Seki
Institutions:
Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo,
Institute of Integrated Research, Institute of Science Tokyo
Observed institutions:
Chugai Pharmaceutical Co., Ltd. (Japan),
Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo,
Institute of Integrated Research, Institute of Science Tokyo
ORCID:
0009-0002-1980-698X
Observed ORCID:
0009-0002-1980-698X
OpenAlex ID:
A5114222632
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
·
Cancer Research Communications
·
10
PDF
Cycling persister clones with elevated NR2F1-mediated cholesterol biosynthesis cause chemotherapy resistance
2026
·
Hajime Sato
, Taku Sato
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 5 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 6 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2025
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
PDF
Supplementary Table 5 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
PDF
Figure 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Table 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Supplementary Table 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
PDF
Supplementary Table 6 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Data from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
2024
·
Takafumi Koyama
, Kan Yonemori
, et al.
Show more works
View as search
Works count:
27
Citation count:
10
H-index:
1
I10-index:
1
Year
Topic
Type